Complex issues of early diagnosis of systemic lupus erythematosus in children
Keywords:systemic lupus erythematosus, diagnosis, children
AbstractData on the current clinical manifestations of systemic lupus erythematosus (SLE) in children and adolescents are presented with a description of the polymorphism of individual symptoms of skin lesions, musculoskeletal system and internal organs, which are difficult for early diagnosis of the disease. The questions of classification analysis of SLE are highlighted, attention is focused on the fact that classification criteria are not always sufficient for early diagnosis of the disease in childhood, which in some cases leads to the “loss” of patients with not fully formed syndromes and/or atypical forms of the disease. The diagnostic criteria for SLE of Systemic Lupus Collaborating Clinics (2012) are quite informative, but they have not been widely adopted in the clinical practice of pediatric rheumatology. American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria (2017) are provided. The results of dynamic monitoring of 22 patients who were treated in the children’s clinic of the Institute over the past 10 years are presented. It is shown that in 28 % of patients the diagnosis was verified only with repeated hospitalizations, in 10 % — almost 6 years after the onset of the disease. The clinical cases of SLE are described: in a patient with a primary chronic course (lesions of the skin and musculoskeletal systems) and a child with a subacute severe course of the disease with kidney damage. The issues of their diagnosis in the onset of the disease are discussed using the classification criteria for SLE proposed by ACR/EULAR (2017). The use of modern clinical and immunological criteria for the diagnosis of SLE in most cases allows you to establish the diagnosis at an earlier stage of the disease and to start timely the pathogenetic therapy.
Alexeeva EA, Dvoryakovskaya TM, Nikishina IP, Denisova RV, Podchernyaeva NS, Sukhorukikh OA, Shubina LS. Systemic lupus erythematosus: clinical recommendations, Part 1. Voprosy sovremennoj pediatrii. 2018;17(1):19–37. doi: 10.15690/vsp.v17i1.1853.
O'Gorman WE, Kong DS, Balboni IM, et al. Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients. J Autoimmun. 2017;S0896-8411(16)30412-7. doi:10.1016/j.jaut.2017.03.010.
Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–1172. doi:10.1136/ard.2006.068676.
Zhang CX, Cai L, Shao K, et al. Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus. Pediatr Nephrol. 2018;33(5):837–845. doi:10.1007/s00467-017-3867-1.
Haddon DJ, Diep VK, Price JV, Limb C, Utz PJ, Balboni I. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):162. Published 2015 Jun 17. doi:10.1186/s13075-015-0682-6.
Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–556. doi:10.1016/j.jpeds.2007.09.019.
Bogmat LF, Nikonova VV, Shevchenko NS, Bessonova IM. Features of renal dysfunction in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Zdorov`e rebenka. 2017;12(6):663–669. doi: 10.22141/2224-0522.214.171.1247.112834.
Brinks R, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M. Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. Lupus. 2014;23(13):1407–1411. doi:10.1177/0961203314540352.
Deutsche Gesellschaft für Rheumatologie e. V. Diagnostik und Klassifikation. Available from: https://dgrh.de/Start/Versorgung/Diagnostik-und-Klassifikation.html. Accessed:19 March 2015.
Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects. Autoimmune Dis. 2014;2014:321359. doi:10.1155/2014/321359.
Maneiro JR, Lopez-Canoa N, Salgado E, Gomez-Reino JJ. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford). 2014;53(5):834–838. doi:10.1093/rheumatology/ket429.
Kuhn A, Sigges J, Biazar C, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014;171(3):571–579. doi:10.1111/bjd.13006.
Gemeinsamer Bundesausschuss. Dossier zur Nutzenbewertung gemäß§35a SGBV - Belimumab (Benlysta) Modul 1. Available from: https://www.g-ba.de/downloads/92-975-94/2012-01-27_Modul1_Belimumab.pdf. Accessed: 19 March 2015.
Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362–1365. doi:10.1016/j.transproceed.2014.01.012.
Copyright (c) 2020 O.M. Mukvich, L.I. Omelchenko, O.A. Belska, I.V. Dudka, T.A. Ludvik, A.M. Matskevich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.